In patients with oesophageal cancer, metabolic reprogramming of the glutathione metabolism, as well as detoxification of ROS by activation of NFE2L2, enhances cancer progression, leading to poor clinical outcomes. This evidence concerns the gene NFE2L2 and cancer.